AMY2B

Across TCGA pan-cancer cohorts, AMY2B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AMY2B data layer compared with 28 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher AMY2B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated AMY2B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, OV, and SARC are the cancer types where AMY2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.964	0.621	.002	36	view →
OV	DFS	Median	II,III,IV	0.214	0.541	.023	18	view →
SARC	OS	Median	All	0.185	0.750	<.001	15	view →
CESC	DFS	Median	II,III,IV	0.140	0.785	<.001	12	view →
HNSC	OS	Median	IV	0.130	0.733	.001	12	view →
STAD	DFS	Median	III,IV	0.112	0.580	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AMY2B–UCEC (DFS)

Open the UCEC breakdown →